ARIA ARIAD Pharmaceuticals, Inc.

ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Rigrodsky & Long, P.A.:

  • Do you own shares of ARIAD Pharmaceuticals, Inc. (NASDAQ GS: ARIA)?
  • Did you purchase any of your shares prior to January 9, 2017?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARIAD Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NASDAQ GS: ARIA) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Takeda Pharmaceutical Company Limited (“Takeda”), in a transaction valued at approximately $5.2 billion.

Click here to learn more: http://rigrodskylong.com/investigations/ariad-pharmaceuticals-inc-aria.

Under the terms of the agreement, shareholders of ARIAD will receive $24.00 in cash for each share of ARIAD common stock.

The investigation concerns whether ARIAD’s board of directors failed to adequately shop the Company and obtain the best possible value for ARIAD shareholders before entering into an agreement with Takeda.

If you own the common stock of ARIAD and purchased your shares before January 9, 2017, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to [email protected], or at: http://rigrodskylong.com/investigations/ariad-pharmaceuticals-inc-aria.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

EN
09/01/2017

Underlying

ARIAARIAD Pharmaceuticals, Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ARIAD Pharmaceuticals, Inc.

MarketLine Department
  • MarketLine Department

Kalobios Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partner...

Summary Marketline's Kalobios Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Kalobios Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive ...

MarketLine Department
  • MarketLine Department

ARIAD Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partners...

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights United States

 PRESS RELEASE

ARIAD Announces Submission of Marketing Authorization Application for ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the European Medicines Agency (EMA). ARIAD is seeking marketing approval in the European Union of brigatinib in adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have been previously treated with crizotinib. The U.S. Food and Drug Administration...

 PRESS RELEASE

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) (“ARIAD” or the “Company”) relating to the proposed buyout of ARIAD by Takeda Pharmaceutical Company Limited. Under the terms of the agreement, ARIAD shareholders are anticipated to receive $24.00 in cash for each share of ARIAD common sto...

 PRESS RELEASE

ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of ARIAD Pharmaceuticals, Inc. (NASDAQ GS: ARIA)? Did you purchase any of your shares prior to January 9, 2017? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARIAD Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NASDAQ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch